Introduction
Agonists of free fatty acid receptor 1 (FFA1, also known as GPR40 prior to its de-orphanizationng in 2003) hold a particular promise have the potential to becomeare an attractive alternative to the currently used anti-diabetic agents, most of which lower glucose levels irrespective of the basal blood glucose concentration and can cause hypoglycemia. 1 FFA1 is highly expressed in the insulin-expressing beta cells of the pancreas and increases insulin secretion in a glucose-dependent manner, thus reducing risk of causing hypoglycemia.Under normal glycemiahomeostasis, FFA1 expression (primarily, in pancreatic islets of Langerhans) is low and increases only in hyperglycemic state. At higher expression levels, activation of the receptor by small molecule agonists triggers a signaling cascade that raises the levels of insulin, lowers the glucose levels and, consequently, downregulates FFA1 itself. 2 Thus, the new therapeutic approach does not carry the danger of causing hypoglycemia (i. e. bringing the blood glucose concentration to dangerously low levels). Development of FFA1 agonists could provide therefore a new class of therapeutic agents This has led to an extensive research effort aimed at developing a new class of agents to treat type 2 diabetes mellitus (T2DM). 3 However, tThe area of FFA1agonist-based theraputic targeting therapy was adversely affected by the late-2013 discontinuation of phase III trial of Takeda's first-in-class agent fasiglifam (TAK-875). 4 At the time of writing this manuscript, merely one clinical trial of an FFA1 agonist (Piramal's compound P11187 of the undisclosed structure) was conducted. 5 The unexpected toxicity issues aside, the antidiabetic efficacy of TAK-875 was established in the course of Takeda's clinical investigation of the drugtrails, thereby providing the proof-of-principle for the entirely new therapeutic approach. 6 At the time of writing this manuscript, merely one clinical trial of an FFA1 agonist (Piramal's compound P11187 of the undisclosed structure) has been conducted. 5 ThereforeIt is expected that, the future quest for efficacious and safe FFA1 agonists should primarily focus on tackling their liver toxicity profile. 7 The toxicity has been linked to the high lipophilicity of TAK-875 as well as most reported FFA1 agonists. 7 An iIncrease ining the total polar surface area (TPSA, Å 2 ) of FFA1 agonists could, in principle, provide a straightforward solution to the problem. However, TAK-875 and many other advanced compounds of this class (such as Amgen's AMG-837, 8 and Eli Lilly's LY2881835 3 ) are based on the 3-[4-(benzyloxy)phenyl]propanoic acid core, which mimics the fatty acid endogenous ligands of the receptor (Figure 1 ). Hence, imparting too much polarity to a FFA1 agonist may simply render the ligand inactive. One effective approach to fine-tuning the lipophilicity profile of FFA1 agonists is to 'decorate' the 3phenylpropahoic acid scaffold with polar heterocyclic moieties. 9 Alternatively, thise scaffold itself could be replaced with heterocyclic isosteres (as in Takeda's compounds 1 10 , 2 11 and 3 12 as well as Amgen's indole-based compound 4 13 shown in Figure 2 ).
Recently, we have reported on the design and synthesis of a series of compounds containing the 3-(1,3,4thiadiazol-2-yl)propionic acid moiety (cLogP = -0.09) in lieu of the 3-phenylpropanoic acid moiety (cLogP = 1.84). 14 The best compound in the series (5) displayed moderate agonist potency against GPR40 FFA1 (EC50 = 5.93 µM) and an excellent in vitro ADMET profile (plasma protein binding, aqueous solubility and microsomal stability). The lower potency of 5 (compared, for example to TAK-875, GPR40 EC50 = 0.014 µM 15 ) can be rationalized by the overly polar character of the 1,2,41,3,4thiadiazole-2-carbozamide used in lieu of the (4-benzyloxy)phenyl moiety (vide supra). In this work, we investigated two compound series that stem from the initial series (represented by compound 5): i.
1,2,41,3,4-thiadiazole-2-carbozamides 6 designed to bring back the lipophilicity of the series (introduction of an additional phenyl ring results in a cLog P increase by two units 16 ) and thus improve its potency; ii. 3-phenylpropanoic acids 7 containing the 1,2,41,3,4-thiadiazole-2-carbozamide periphery, designed with the same 'polar appendage' approach in mind as explored by us earlier 9 ( Figure   3 ). 
Results and discussion
Compounds 6a-e were synthesized from known 2-chloroacetamides 8 according to the previously reported protocol. 14, 17 Both sets of potential GPR40 agonists (6a-e and 7a-l) were tested for FFA1 activation using a calcium flux assay conducted on Chinese hamster ovary (CHO) cells. All compounds were tested in concentration-response (% GPR40 activation) mode in order to determine EC50 values, which are presented in Table 1 . In analyzing the data on biological activity against FFA1, it should be borne in mind that the anilide periphery in the series of the receptor agonists represented by compound 5 was designed so as to impart higher lipophilicity to otherwise overly hydrophilic 3-(1,2,41,3,4-thiadiazol-2-yl)propanoic acid scaffold (vide supra) and thus increase affinity to the receptor (the physiological activation of which is triggered by endogenous fatty acid ligands like eicosatienoic acid). 18 From the data obtained for a even a small set (6a-e) of higher-logP analogs of compound 5, it becomes apparent that our hypothesis of using lipophilicity as a driver of potency against FFA1 was correct. Indeed, four out of five analogs had significantly higher potency compared to 5, (with the best compound, 6a, leading into the submicromolar range). The lower potency of 6e most is likely due to conformational rigidity requirement in the portion of the molecule opposite to carboxylic acid functionality, which is present in biphenyl analogs 6a-d and is lost after introduction of the -CH2O-linker in 6e.
The overall very satisfactory potency profile of compounds 7a-l suggests that 1,2,41,3,4-thiadiazole-2carboxamide moiety was a suitable periphery group to add to the 3-phenylpropanoic acid core in order to improve affinity to FFA1. The agonist activity in this series appears to be particularly sensitive to the substitutions in the anilide moiety, thus attesting for the importance of the latter for building efficient interactions with the receptor. Clearly, substitution in position 4 of the phenyl ring is particularly detrimental for the activity (7b, 7g, 7e, 7k). Substituents in positions 2 and 3 seem to be well tolerated, It was important to establishWe next evaluated the selectivity profile of the most potent GPR40 agonists from both series studied here (6a, 6c, 7c and 7j) against other GPCRs binding free fatty acidsfree fatty acid receptors (FFA3/GPR41, FFA2/GPR43 and FFA4/GPR120). While the four FFARs share a significant similarity, GPR41 FFA2 and GPR43 FFA3 agonists are usuallyhave a preference in binding shorter short-chain fatty acids while GPR40 FFA1 and GPR120 FFA4 have a higher affinity to medium-and long-chain fatty acids. 19, 20 As it is seen from the activation activity data against this panel of GPRsGPCRs, the four lead compounds displayed high selectivity for GPR40 FFA1 (Table 2) . 
a Each values is an average of n = 4 in the presence of 0.1% BSA. To gain a structural understanding of improved potency of 6a compared to 5, we have docked 6a and 5
in the FFA1 binding site. As visualized in Figure 4A , both compounds have a similar orientation within the binding cavity forming hydrogen bonds with R1835.39, Tyr913.37, Tyr2406.51 and the backbone of L1384.57. While the more potent agonists (TAK-875, AMG 837 and LY2881835) substitute the 1,3,4thiadizole with a more hydrophobic benzene ring, thiadizole is still well accommodated within the binding site. This can be justified by its propensity to form π-π interactions with W174EL2 and possibly F873.33.
The phenyl ring of 5 is at the interhelical space of helices 3 and 4, forming hydrophobic interactions with V843.30 , F883.34 and F1424.61 ( Figure 4B ). In contrast, the same phenyl ring of 6a positions deeper within the binding cavity forming π-π stacking interactions with F883.34 and F1424.61 ( Figure 4C ). It appears that the addition of a second phenyl ring in 6a slightly pulls the molecule inside the helical bundle. This is due to involvement of the second phenyl ring in hydrophobic interactions with V843.30 and L1354.54 and the π-π stacking interaction with F883.34. The formation of the aromatic network with the receptor could explain the 10-fold increase in potency observed for 6a compared to 5. a Each value is an average of n = 2, measured at c = 1 µM. b Data were inconclusive due to compound's low plasma stability.
Since we were able to reach low micromolar to sub-micromolar potency in both compound series (6 and 7), we were also keen on in assessing the preliminary ADME profile, (particularly with respect to plasma and liver microsomal stability) forof the most active compounds from these series. As it is evident from unfortunate aspect (which could be related to the presence of metabolically prone 4-phenoxy-1,2,41,3,4thiadiazole linkage in 7a-l) will undoubtedly affect the prospects of developing compounds belonging to series 7 as pharmacological tools or drug candidates. a Each value is an average of n = 4, measured at c =concentration 20 µM.
The cytochrome P450 inhibition profile assessed for five principal isoforms (1A2, 2C9, 2C19, 2D6 and 3A4) 23 demonstrated that the occasional isoform-selective inhibition is not scaffold-related. Clearly, among two compounds in each series, compounds 6c and 7c have a markedly 'cleaner' profile and, hence, lower likelihood of causing drug-drug interactions due to CYP inhibition. 24 
Conclusions
We have explored two chemical series as FFA1 receptor agonists: one (6) clearly standsing out in terms of the overall potency and ADME profile.
Experimental section

General experimental
All reactions were conducted in oven-dried glassware . Melting points were measured with a Buchi В-520 melting point apparatus and were not corrected. Analytical thin-layer chromatography was carried out on Silufol UV-254 silica gel plates using appropriate mixtures of ethyl acetate and hexane.
Compounds were visualized with short-wavelength UV light. 1 H NMR and 13 C NMR spectra were recorded on Bruker MSL-300 spectrometers in DMSO-D6-d6 using TMS as an internal standard. Mass spectra were recorded using Shimadzu LCMS-2020 system with electron impact (EI) ionization. All and reagents and solvents were obtained from commercial sources and used without purification.
All mass-spectroscopic measurements required for determination of ADME properties were performed using Shimadzu VP HPLC system including vacuum degasser, gradient pumps, reverse phase HPLC column, column oven and autosampler. The HPLC system was coupled with tandem mass spectrometer API 3000 (PE Sciex). The TurboIonSpray ion source was used in both positive and negative ion modes.
Acquisition and analysis of the data were performed using Analyst 1.5.2 software (PE Sciex). Hz, 1H), 1.42 (s, 4H); 13 
Synthetic
General procedure for the preparation of compounds 6a-e
To a suspension of elementary sulfur (512 mg, 16.0 mmol) in dry DMF (20 mL) was sequentially added (in dropwise fashion) triethylamine (2.25 mL, 16.0 mmol) and morpholine (1.06 mmol) and the resulting mixture was stirred for 30 min. Then it was treated with a solution of respective 2-chloroacetamides 8 (0.5 mmol). The mixture was stirred overnight, poured into water (50 mL) and the resulting precipitate was separated by filtration and air-dried. It was then suspended in acetone (50 mL) and the insoluble residue of excess of unreacted sulfur was filtered off and discarded. The filtrate was evaporated to dryness and the dry residue was dissolved in dry DMF (15 mL), treated with hydrazine hydrate (2.5 mL) and stirred for 12 hours. The reaction mixture was poured into water, the pH of the aqueous medium was adjusted to 5.0 with 2M aqueous HCl. The resulting precipitate of 10 was filtered off and used in the next step without further purification (purity of at least 90% was estimated based on 1 H NMR analysis). Thiohydrazide 10 thus obtained was placed in a thick-walled crew-capped glass tube along with succinic anhydride (1.2 mmol) and glacial acetic acid (3.0 mL). The reaction mixture was heated at reflux temperature on vigorous stirring over 2 hours, cooled down and poured into water (25 mL).
The precipitate formed was filtered off and air dried to deliver analytically pure compounds 6a-e in yields indicated.
3-{5-[(3'-methylbiphenyl-3-yl)carbamoyl]-1,3,4-thiadiazol-2-yl}propanoic acid (6a).
Compound 6a was obtained as a white solid (150 mg, 82% 
3-{5-[(3'-chlorobiphenyl-3-yl)carbamoyl]-1,3,4-thiadiazol-2-yl}propanoic acid (6b).
Compound 6b was obtained as a white solid (155 mg, 80% 
3-{5-[(4'-fluorobiphenyl-3-yl)carbamoyl]-1,3,4-thiadiazol-2-yl}propanoic acid (6c).
Compound 6c was obtained as a white solid (145 mg, 78% 
3-(5-{[3-(furan-2-yl)phenyl]carbamoyl}-1,3,4-thiadiazol-2-yl)propanoic acid (6d).
Compound 6d was obtained as a white solid (110 mg, 64% 2.2.5. 3-(5-{[4-(benzyloxy)phenyl]carbamoyl}-1,3,4-thiadiazol-2-yl) 
General procedure for the preparation of compounds 7a-l
Compounds 7a-l were prepared in the same manner and on the same scale (0.5 mmol of 2chloroacetanilides 11) as described above for the preparation of compounds 6a-e, except for the 3.11. 3-[4-({5-[(4-methylphenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy) 
Molecular modeling
Protein structure source and preparation for docking
The crystal structure of FFA1 complexed with TAK-875, with PDB code: 4phu was used for docking studies. 25 All in silico work pertaining to docking and protein preparation was carried out using the specified modules within Schrodinger's maestro, version 2016-1. 26 To prepare FFA1 for docking, hydrogens, missing atoms and alternate residue positions were defined followed by optimization of the hydrogen bonding network by re-orienting hydroxyl and amide groups of Asn and Gln and identifying an appropriate orientation of the imidazole ring of His residues using Protein Preparation Wizard. 27
Docking protocol.
The mutant Ala88 made for thermal stability during crystallization was mutated back to Phe followed by extensive sampling for the side-chain position. Careful positioning of the phenyl group was needed as Phe88 can be considered as an import residue in stabilizing protein-ligand binding and may influence docking results substantially. The conformation was sampled using MacroModel's Conformational Search. 28 To alleviate any protein strain occurring from this point mutation, while reducing deviation from the original crystal structure coordinates, a tightly controlled, two stage minimization protocol was applied, i.e. hydrogen only minimization followed by a minimization based on constraints set from the Commented [DM9]: I don't believe it makes sense to have separate subtitle for docking protocol, as protein preparation is contained in both.
X-ray derived B factors. MinimisationMinimization was performed using MacroModel. 28 In deciding on a final position of Phe88 and ensuring a correct docking protocol was used, TAK-875 was re-docked onto the receptor and compared to the position obtained in the crystal structure, an RMSD of < 2.5 Å.
Prior to docking, agonists were created manually in maestro, the 2D structures were then optimized to produce a low-energy 3D structure using LigPrep. 29 Glide 30 was used for receptor grid generation and ligand docking. The centroid of the receptor grid was defined by using TAK-875's crystal structure conformation. Ligands were docked using the extra precision (XP) algorithm while enhancing the planarity of conjugated pi groups. The OPLS3, all-atom force-field was employed for all calculations.
In labelling the protein residues of FFA1 in figure 4 and figure 5 the number in subscript represents the Ballesteros Weinstein indexing system. 
Determination of the distribution coefficient (LogD, pH 7.4)
The partitioning ratio of compounds 6a, 6c, 7c and 7l and one reference compound (logDpH7 = 2.93) was determined in n-octanol -phosphate buffer saline (PBS) using shake-flask method which consists of equilibrating a certain amount of a solute within the biphasic system and determining the concentration in each phase using LC-MS/MS. Equilibration was carried out in Eppendorf-type polypropylene microtubes in duplicates. 5 µL aliquots of 10 mM DMSO stock solution were added to a manually preequilibrated mixture of PBS (500 µL) and n-octanol (500 µL) and the resulting mixture was shaken for 1h at 30 rpm. Phase separation was achieved by centrifugation for 2 min at 6000 rpm. The n-octanol phase was diluted 100-fold with 40% aqueous acetonitrile and the PBS phase was diluted 10-fold with 5% aqueous acetonitrile. The partitioning ratio (D) was calculated using the formula:
, where S0 -peak area of the analyte in the n-octanol phase, Sp -peak area of the analyte in PBS phase.
Assessment of metabolic stability in mouse liver microsomes
The metabolic stability of compound 6a, 6c, 7c and 7l as well as the reference compound (Propranolol) was measured in liver microsomes at five time points over 40 minutes using HPLC-MS. Metabolic stability is defined as the percentage loss of parent compound lost over time in the presence of a metabolically active test system, such as rodent liver microsomal fractions.
Mouse hepatic microsomes were isolated from pooled (50), perfused livers of BALB/c male mice according to the standard protocol. 31 The batch of microsomes was tested for quality control using a commercial comparator preparation (Sigma-Aldrich M9441) and verapamil as reference compound.
Microsomal incubations were carried out in 96-well plates in 5 aliquots of 40 μL each (one for each time point added to the other chamber. After that, HTD96b dialyzer was covered with adhesive sealing film and incubated at 37°C on an orbital shaker at 100 rpm for 5 hours. An aliquot of the content of each chamber had been taken and mixed with the same volume aliquot of the blank opposite matrix. In order to define non-specific loss of the compound during this assay, standard solution was created by mixing an aliquot of spiked plasma, which was incubated at 37°C without dialysis, with blank buffer. Sample of 1 μM series was diluted with 100% acetonitrile 10-fold with subsequent plasma proteins precipitation by centrifuging at 6000 rpm for 5 minutes. Incubations were performed in quadriplicates. Supernatants were analyzed using HPLC system coupled with tandem mass spectrometer. The unbound compound fraction is calculated as the peak ratio of the analyte in the buffer compartment divided by the same parameter in the corresponding plasma compartment.
The following equation was used to determine the extent of plasma protein binding: 
Analysis of stability in mouse plasma
